French Drug Prices Remain Below Euro Average: SNIP

8 June 1997

In France, the price of reimbursable drugs is regularly decreasing inreal terms, says the SNIP, the country's pharmaceutical manufacturers' association. Moreover, the association goes on, the price level of drugs in France continues to be inferior to that seen in the main European industrialized countries.

Current rates of drug reimbursement in France are 100% for products which are recognized as both irreplaceable and particularly expensive, 35% for drugs used mainly to treat pains and non-serious conditions and 65% for all other medicines. Under certain conditions, eg severe disease or incapacity, social insurers are able to benefit from exemption of the patient's copayment due for the different groups of reimbursable products.

Only 8%-9% of people are exempt from copayment, but their share of drug spending was around 45.3% of the total in 1996, SNIP notes. French consumer spending on drugs is also said to be low. SNIP puts the average per capita spend at 6 French francs ($1.04) per day, compared with 36.3 francs on food and beverages, 11.6 francs on clothing (shoes included), 47.1 francs on housing, heating and lighting, 16.2 francs on entertainment and 3.2 francs of tobacco.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight